2013-03-26
Angiotech Pharmaceuticals sells its interventional products business back to previous overseer Argon Medical for $362.5 million, planning to use part of the funds to repay repay all of its outstanding debts.
Angiotech Pharmaceuticals plans to retire all of its outstanding debt obligations with part of the $362.5 million it stands to gain through the sale of its interventional products business back to Argon Medical Devices.
News Well, Deals Roundup, Mergers & Acquisitions, Venture Capital/Private Equity, Wall Street Beat
read more